Merck KGaA Buys Mirus Bio for $600 Million
By Ian Walker
Germany's Merck KGaA is buying life-science company Mirus Bio for $600 million as it expands its life science business sector.
The life-sciences and electronics company said late Wednesday that it expects the deal to close in the third quarter of this year.
Mirus Bio, based in Madison, Wis., develops transfection reagents that help to introduce genetic materials into cells.
"This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future," Chairman and Chief Executive Belen Garijo said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 23, 2024 01:12 ET (05:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations